Final answer:
The absolute risk reduction (ARR) for CV death in the EMPA-REG Outcomes Trial was not provided, but an example calculation for a new medication showed an ARR of 10.27% using rates from a control and a treatment group.
Step-by-step explanation:
Absolute Risk Reduction in the EMPA-REG Outcomes Trial The absolute risk reduction (ARR) for CV death in the EMPA-REG Outcomes Trial was not directly provided in the question or the references. However, based on the given data for a hypothetical new medication, we can calculate the ARR using the formula: ARR = (control event rate) - (treatment event rate).
In the provided scenario with the new medication, the control group had 68 patients developing the disease out of 224, which is a rate of 30.36%, and the treatment group had 45 out of 224, a rate of 20.09%. Therefore, the ARR for this medication would be 10.27%. It's important to apply this calculation to the correct trial data when calculating the ARR for the EMPA-REG Outcomes Trial. The presented statistics are an example of how to perform the calculation when the appropriate figures are known.